Children's Oncology Group's 2023 blueprint for research: Liver tumors

Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30576. doi: 10.1002/pbc.30576. Epub 2023 Jul 26.

Abstract

Liver tumors account for approximately 1%-2% of all pediatric malignancies, with the two most common tumors being hepatoblastoma (HB) and hepatocellular carcinoma (HCC). Previous Children's Oncology Group studies have meaningfully contributed to the current understanding of disease pathophysiology and treatment, laying groundwork for the ongoing prospective international study of both HB and HCC. Future work is focused on elucidating the biologic underpinnings of disease to support an evolution in risk categorization, advancements in the multidimensional care required to treat these patients, and the discovery of novel therapies.

Keywords: hepatoblastoma; hepatocellular; international; liver; pediatric.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Carcinoma, Hepatocellular* / pathology
  • Carcinoma, Hepatocellular* / therapy
  • Child
  • Combined Modality Therapy
  • Hepatoblastoma* / pathology
  • Hepatoblastoma* / therapy
  • Humans
  • Liver Neoplasms* / pathology
  • Liver Neoplasms* / therapy
  • Prospective Studies